News
Resources
Blog
Sites
Tom Wilbur is Senior Director of Public Affairs at PhRMA focused on opinion research, message development and political communications. Prior to joining PhRMA in 2019, Tom worked on Capitol Hill and on political campaigns for eight years, most recently responsible for communications and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the office enjoys spending time with friends and family, reading, running, hiking, and golfing.
Recent Posts
Health care costs and affordability remain a major challenge for most Americans, even among those with insurance. According to a March Gallup poll, nearly one-in-five (18%) U.S. adults report that if...
Read More
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
By Tom Wilbur | March 11, 2021
On January 19, 2021 – the last full day of the Trump administration – CMS released a Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This model would provide...
Read More
Key excerpts: PhRMA submits comments to keep the six protected classes protected
By Tom Wilbur | February 19, 2021
Earlier this month, PhRMA submitted comments to CMS regarding the Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This RFA was released on January 19, 2021 –...
Read More
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
By Tom Wilbur | February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...
Read More
Action needed to preserve the six protected classes
By Tom Wilbur | February 3, 2021
In the final hours of the previous Administration’s time in office, the Center for Medicare & Medicaid Innovation (the Innovation Center) (CMMI) announced new changes for CY 2022 to an existing...
Read More
Key facts: The final rebate rule will be a positive change for patients
By Tom Wilbur | January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a policy...
Read More
End of year Part D reading List
By Tom Wilbur | December 18, 2020
Happy Holidays, Part D readers, and thank you for following along this year as we explored the impact of Medicare Part D and the important role the program plays for seniors and those with...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access...
Read More
Insights from the election: Meeting voters where they are on health care
By Tom Wilbur | December 15, 2020
The 2020 election was defined by a wide range of unique, and in some cases, unprecedented factors. From a global pandemic to never before seen rates of mail-in ballot casting and record voter turnout...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | December 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
